A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)

Summary

A study to evaluate the response of growth factor signatures (GFS) to a single dose of dalotuzumab in participants with triple negative (TN) or estrogen receptor (ER)-positive luminal B breast cancer. The primary hypothesis is that dalotuzumab will induce a decrease in the GFS in at least 40% of participants.

Timeline

Start

2008-09-30

Primary completion

2010-02-17

Completion

2010-02-17

Drugs

Indications